Showing results (571-580 of 645) with videos related to
Sort By:
Pageof 65
Journal of Parkinson'S Disease|September 19, 2017
App-Based Bradykinesia Tasks for Clinic and Home Assessment in Parkinson's Disease: Reliability and ResponsivenessDustin A Heldman, Enrique Urrea-Mendoza, Lilia C Lovera, et al.Neurology|July 14, 2004
Development and initial validation of a screening tool for Parkinson disease surgical candidatesM S Okun, H H Fernandez, O Pedraza, et al.Frontiers in Neurology|March 14, 2022
Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension StudyRobert A Hauser, Hadas Barkay, Hubert H Fernandez, et al.Cell|May 22, 2003
Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1Hung-Kai Chen, Pedro Fernandez-Funez, Summer F Acevedo, et al.The Lancet. Neurology|July 15, 2026
Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trialHubert H Fernandez, Perminder Bhatia, Leslie Cloud, et al.Journal of Neurosurgery|September 21, 2010
A closer look at unilateral versus bilateral deep brain stimulation: results of the National Institutes of Health COMPARE cohortHoutan A Taba, Samuel S Wu, Kelly D Foote, et al.Neurosurgery|August 22, 2019
Factors Associated With Postoperative Confusion and Prolonged Hospital Stay Following Deep Brain Stimulation Surgery for Parkinson DiseaseHesham Abboud, Gencer Genc, Saira Saad, et al.Human Reproduction (Oxford, England)|June 24, 2024
Evaluating the safety of high-intensity focused ultrasound treatment for rectal endometriosis: results from a French prospective multicentre study including 60 patientsG Dubernard, E Maissiat, G Legendre, et al.Parkinsonism & Related Disorders|July 27, 2020
Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosisClive G Ballard, David L Kreitzman, Stuart Isaacson, et al.Transplantation|January 15, 1997
High-dose donor bone marrow infusions to enhance allograft survival: the effect of timingC Ricordi, T Karatzas, J Nery, et al.Pageof 65